دورية أكاديمية
أعرض في EDS

The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
المؤلفون: Gao J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Song Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Kou X; Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China., Tan Z; Department of Thoracic Surgery, Xingtai People's Hospital, Xingtai, China., Zhang S; Department of Gastrointestinal Oncology, Shandong First Medical University Cancer Hospital, Shandong Cancer Hospital, Jinan, China., Sun M; Department of Medical Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China., Zhou J; Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China., Fan M; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Zhang M; Department of Integrated Traditional and Western Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China., Song Y; Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China., Li S; Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, China., Yuan Y; Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China., Zhuang W; Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, China., Zhang J; Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China., Zhang L; Department of Oncology, Chongqing University Three Gorges Hospital, Chongqing, China., Jiang H; Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China., Gu K; Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Ye H; Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China., Ke Y; Shanghai Henlius Biotech, Inc., Shanghai, China., Qi X; Shanghai Henlius Biotech, Inc., Shanghai, China., Wang Q; Shanghai Henlius Biotech, Inc., Shanghai, China., Zhu J; Shanghai Henlius Biotech, Inc., Shanghai, China., Huang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
المصدر: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (10), pp. e7203.
نوع المنشور: Journal Article; Meta-Analysis
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
مواضيع طبية MeSH: Liver Neoplasms*/secondary , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , Esophageal Squamous Cell Carcinoma*/drug therapy , Esophageal Squamous Cell Carcinoma*/secondary , Esophageal Squamous Cell Carcinoma*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Esophageal Neoplasms*/mortality, Humans ; Male ; Immune Checkpoint Inhibitors/therapeutic use ; Female ; Middle Aged ; Randomized Controlled Trials as Topic ; Aged ; Treatment Outcome ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage
مستخلص: Objective: To explore the efficacy of serplulimab plus chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with liver metastases.
Methods: A post hoc exploratory analysis of ASTRUM-007 study was performed, focusing on the association between the liver metastases status and the clinical outcomes. A systematic literature search of electronic databases was conducted to identify eligible randomized controlled trials for the meta-analysis. Study-level pooled analyses of hazard ratios (HRs) for PFS according to liver metastases were performed.
Results: The post hoc analysis of ASTRUM-007 showed that although patients with liver metastases had a worse prognosis comparing with the non-liver metastases patients in both treatment arms (serplulimab plus chemotherapy arm: median PFS, 5.7 vs. 6.6 months, HR 1.57 [95% CI, 1.15-2.13]; median OS, 13.7 vs. 15.3 months, HR 1.48 [95% CI, 1.09-1.98]; placebo plus chemotherapy arm: median PFS, 4.3 vs. 5.5 months, HR 1.58 [95% CI, 1.01-2.39]; median OS, 10.3 vs. 11.2 months, HR 1.32 [95% CI, 0.84-2.00]), OS and PFS benefits derived from serplulimab plus chemotherapy versus placebo plus chemotherapy in this study were observed in both patients with liver metastases (HR of PFS: 0.60; 95% CI, 0.37-0.97; HR of OS: 0.68; 95% CI, 0.43-1.11) and the non-liver metastases patients (HR of PFS: 0.62; 95% CI, 0.49-0.80; HR of OS: 0.69; 95% CI, 0.55-0.87) with similar magnitude. Three randomized controlled trials were included in the meta-analysis. Pooled HRs demonstrated that the addition of anti-PD-1 antibodies significantly improved PFS compared to chemotherapy alone regardless of liver metastases status.
Conclusions: This study reveals that the presence of liver metastases is a poor prognostic factor but does not affect the improvements in both PFS and OS brought by adding PD-1 blockade to chemotherapy in ESCC patients. Predictive biomarkers for survival in these patients warrant further investigation.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
References: Thorac Cancer. 2022 Nov;13(21):2960-2969. (PMID: 36168908)
Gastroenterology. 2022 Sep;163(3):649-658.e2. (PMID: 35671803)
Cancer. 2020 Jan 1;126(1):86-97. (PMID: 31584722)
Clin Cancer Res. 2014 Jun 1;20(11):2831-7. (PMID: 24879823)
Lancet. 2021 Aug 28;398(10302):759-771. (PMID: 34454674)
Sci Rep. 2016 Jun 21;6:28280. (PMID: 27323696)
Nat Med. 2023 Feb;29(2):473-482. (PMID: 36732627)
J Thorac Dis. 2017 Sep;9(9):3023-3030. (PMID: 29221275)
Gut. 2020 Sep;69(9):1564-1571. (PMID: 32606208)
Cancer Control. 2022 Jan-Dec;29:10732748211072976. (PMID: 35037487)
JAMA Oncol. 2019 Oct 01;5(10):1411-1420. (PMID: 31343665)
JAMA Netw Open. 2023 Feb 1;6(2):e230400. (PMID: 36811859)
Gastroenterology. 2018 Jan;154(2):360-373. (PMID: 28823862)
Arq Bras Cir Dig. 2016 Nov-Dec;29(4):215-217. (PMID: 28076472)
Cancer Immunol Res. 2017 May;5(5):417-424. (PMID: 28411193)
Cancer Manag Res. 2017 Dec 06;9:781-788. (PMID: 29255373)
Lancet Oncol. 2017 Nov;18(11):1483-1492. (PMID: 28967485)
N Engl J Med. 2022 Feb 3;386(5):449-462. (PMID: 35108470)
Ann Oncol. 2022 Oct;33(10):992-1004. (PMID: 35914638)
Curr Treat Options Oncol. 2011 Mar;12(1):46-60. (PMID: 21298375)
Nat Med. 2021 Jan;27(1):152-164. (PMID: 33398162)
Ann Oncol. 2004 Jun;15(6):955-9. (PMID: 15151954)
Curr Opin Organ Transplant. 2017 Feb;22(1):71-78. (PMID: 27984276)
Expert Opin Drug Deliv. 2021 Feb;18(2):187-203. (PMID: 32954856)
Cancer Med. 2024 May;13(10):e7203. (PMID: 38769930)
معلومات مُعتمدة: Shanghai Henlius Biotech, Inc; CICAMS-MOMP2022001 Major Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences
فهرسة مساهمة: Keywords: anti‐PD‐1 antibody; chemotherapy; esophageal squamous cell carcinoma (ESCC); liver metastases; meta‐analysis; serplulimab
تواريخ الأحداث: Date Created: 20240521 Date Completed: 20240521 Latest Revision: 20240523
رمز التحديث: 20240523
مُعرف محوري في PubMed: PMC11106639
DOI: 10.1002/cam4.7203
PMID: 38769930
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-7634
DOI:10.1002/cam4.7203